Zydus Lifesciences wins USFDA nod for diabetes drug Zituvimet
The approval of ZITUVIMET is based on research, development, regulatory, and manufacturing work performed by Zydus teams.
Ahmedabad: Pharma major, Zydus Lifesciences Limited, today announced that the U.S. Food and Drug Administration (USFDA) approved its New Drug Application (NDA) for ZITUVIMET (Sitagliptin and Metformin hydrochloride) tablets, 50 mg/500 mg and 50 mg/1000 mg.
ZITUVIMET contains active ingredients sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
The approval of ZITUVIMET is based on research, development, regulatory, and manufacturing work performed by Zydus teams. ZITUVIMET has undergone quality testing for Nitrosamines and potential genotoxic impurities as per current USFDA standards. ZITUVIMET is compliant with current USFDA standards of Nitrosamines in Sitagliptin containing products.
“The ZITUVIMET approval further builds on our previous approval of ZITUVIO (Sitagliptin) and offers an increased accessibility and affordability to healthcare systems with regard to prescription drugs for type II diabetes, said Dr. Sharvil Patel, Managing Director of Zydus Lifesciences Limited.
"The ZITUVIMET approval provides an affordable treatment option for healthcare systems to reduce the rate of growth in drug spending and improves the financial sustainability of the healthcare programs,” he added.
Read also: Zydus Lifesciences bags USFDA approval for type 2 diabetes mellitus drug Zituvio for adults
According to IQVIA (MAT Aug-2023), U.S. market for DPP-IV inhibitors and their combinations is US$ 10 bn.
Read also: Zydus Lifesciences, Lupin to co-market Saroglitazar Mg for chronic liver diseases treatment in India
